TriangleDasatinib (NCT07269470)
Dasatinib trial for Chronic Myeloid Leukemia (NCT07269470). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with newly diagnosed, Philadelphia-chromosome-positive or BCR::ABL1-positive chronic myeloid leukemia in chronic phase. Brief previous treatment is allowed; accelerated or blast-phase disease is excluded, with a defined chromosome-only exception.
The idea: combine dasatinib’s inhibition of growth-promoting kinases with ropeginterferon’s immune and cell-growth effects. Patients take dasatinib orally and receive ropeginterferon injections under the skin. Researchers assess safety and deep reductions in BCR::ABL1 transcripts at twelve months, with longer survival follow-up.
This phase 2 study plans 40 patients. Fadi Haddad leads MD Anderson’s recruiting Houston site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.